文献速递肾小球疾病

老年原发性肾小球疾病:CureGN队列的临床特征、治疗模式与结局

Primary Glomerular Diseases in the Elderly: Clinical Features, Treatment Patterns, and Outcomes in the CureGN Cohort.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-08-07

该回顾性多中心研究基于CureGN队列2014–2023年1562例活检证实的原发性肾小球疾病成人,按诊断年龄分层比较临床病理特征与治疗模式。老年(≥65岁)患者合并症负担更重、入组时eGFR更低,肾硬化组织学特征随年龄增加,但疾病特异性特征相似;老年患者更多接受保守或保类固醇方案,5年超额死亡率为7%–14%,校正后高龄对复合肾脏结局独立保护。

要点

  • 老年起病原发性肾小球疾病表现为eGFR更低、合并症负担更重。
  • 肾硬化(尤其动脉硬化)组织学特征随年龄增长更常见,但疾病特异性特征相似。
  • 老年患者更多接受保守或保类固醇方案,5年超额死亡率7%–14%,校正后高龄对复合肾脏结局独立保护。

核心结论

  • 衰老增加合并症和组织学慢性化,但不改变原发性肾小球疾病的表型;超额死亡和可能的潜在生物学差异塑造老年起病患者的结局。

研究设计与样本

  • 回顾性多中心研究,纳入CureGN队列2014–2023年活检证实的微小病变、FSGS、膜性肾病和IgA肾病/血管炎伴肾炎的成人,按诊断年龄分为18–39岁、40–64岁和≥65岁三组。
  • 共1562例成人,其中211例诊断时≥65岁;704例活检有可用的Cure Glomerulopathy病理分类。

主要发现

  • 老年患者合并症负担更高,入组时eGFR更低:55 [34-75] vs 年轻成人84 [50-115] 和中年成人65 [43-91] ml/min,P < 0.001。
  • 在704例有病理分类的活检中,肾硬化特征(尤其动脉硬化)随年龄增长而增加,而疾病特异性特征在各年龄组相似。
  • 老年患者更多接受保守或保类固醇方案;与年轻成人相比,老年患者5年超额死亡率为7%–14%。
  • 校正模型中,高龄对复合肾脏结局独立保护(亚分布风险比0.65–0.79)。

临床怎么用

  • 对老年原发性肾小球疾病患者应重视合并症管理和肾硬化评估,治疗可更多考虑保守或保类固醇方案。
  • 尽管高龄对复合肾脏结局显示独立保护,但需关注超额死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Elderly onset primary glomerular diseases are characterized by decreased GFR and a higher comorbidity burden compared with younger adult subgroups. Histologic features of nephrosclerosis become more prevalent with advancing age. Excess morbidity, mortality and, possibly, underlying biologic differences, shape outcomes in elderly onset primary glomerular diseases. BACKGROUND: Primary glomerular diseases (PGDs) are not uncommon in elderly patients, where age-related histologic changes, frailty, and multimorbidity overlap with disease-specific drivers of damage. Evidence on the impact of older age at onset on PGD presentation and outcomes remains heterogeneous. This retrospective multicenter study assessed the impact of older age at diagnosis on the clinical-histologic presentation, treatment, and outcome of PGDs. METHODS: Adults with biopsy-proven minimal change disease, FSGS, membranous nephropathy, and IgA nephropathy/vasculitis with nephritis enrolled in Cure Glomerulonephropathy between 2014 and 2023 with available kidney function data were stratified by age at diagnosis into three age groups: young adults (18-39 years), middle-aged adults (40-64 years), and elderly patients (≥65 years). Clinical-histologic features and treatment patterns were compared across age groups, with a focus on elderly patients. Evaluated outcomes included all-cause mortality and a composite kidney outcome (>40% eGFR decline or kidney failure). Cox regression and Fine-Gray models were fitted to evaluate the impact of age on the composite kidney outcome. RESULTS: Among 1562 adults, 211 were aged ≥65 years at diagnosis. Elderly patients exhibited a higher comorbidity burden and lower eGFR at enrollment (55 [34-75] versus 84 [50-115] in young adults and 65 [43-91] ml/min in middle-aged adults, P < 0.001). In 704 biopsies with an available Cure Glomerulopathy Pathology Classification, nephrosclerosis features-particularly arteriosclerosis-increased with advancing age, whereas disease-specific features were similar across age groups. Elderly patients more often received conservative or steroid-sparing regimens. A 5-year excess mortality of 7%-14% compared with young adults was observed in the elderly patients. In adjusted models, older age was independently protective for the composite kidney outcome (subdistribution hazard ratios 0.65-0.79). CONCLUSIONS: Aging adds comorbidity and histologic chronicity without altering PGDs phenotype; excess mortality and, possibly, underlying biologic differences shape outcomes in elderly onset PGDs.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Tedesco M, Mescia F, Ma BM, et al. Primary Glomerular Diseases in the Elderly: Clinical Features, Treatment Patterns, and Outcomes in the CureGN Cohort. Clin J Am Soc Nephrol. 2026. PMID: 42566285. doi:10.2215/CJN.0000001163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。